Odefsey

Odefsey is a fixed-dose tablet combining 25mg of rilpivirine, 200mg of emtricitabine and 25mg of tenofovir alafenamide (TAF). It is manufactured by Gilead Sciences.

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.

The standard dose of Odefsey is one grey tablet once day with food. Odefsey is approved as initial treatment for people with a viral load below 100,000 copies/ml and for people switching from another drug combination with an undetectable viral load regardless of their viral load before treatment.

Odefsey received marketing approval in the United States in March 2016 and in the European Union in June 2016.

For more information on Odefsey’s component drugs, including drug interactions, side-effects and resistance, see rilpivirine, emtricitabine and tenofovir.